The global hydrocephalus shunts market was valued at $291.00 million in 2019 and is projected to reach $322.01 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Growth in the number of ...

Get Instant Summarized Text (Gist) Pulmonary artery denervation (PADN) shows promise as an intervention for pulmonary hypertension, improving key hemodynamic parameters and clinical outcomes. A ...

Original Medicare and Part C should provide a comprehensive pulmonary rehabilitation program for a person who has chronic issues with breathing. Original Medicare includes Part A, which is ...

“Obviously what happened to Jack was a big shunt and very unfortunate, but I think it's one of those things that you see happen once and everybody will recognise, and this is probably the only ...

Get Instant Summarized Text (Gist) Sotatercept, a novel drug administered via subcutaneous injection, has shown significant efficacy in treating advanced pulmonary arterial hypertension (PAH), a ...

If it lands in the lungs, it’s called a pulmonary embolism. Estimates vary widely, but according to the American Lung Association, around 900,000 U.S. adults experience this type of potentially ...

Researchers reveal critical mechanism behind idiopathic pulmonary fibrosis. Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease ...

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...

Cirrhosis is one of the leading causes of mortality from non-communicable diseases, with complications arising as liver function deteriorates. HRS and HPS represent the most severe outcomes of ...

The purpose of this study is to assess the safety, performance, and effectiveness of the Edwards APTURE transcatheter shunt system (“APTURE system”; formerly referred ... There is objective evidence ...

If you are newly diagnosed with PAH, you should be referred to a pulmonary hypertension specialist and if possible be seen at an accredited pulmonary hypertension care center for thorough evaluation.